These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 18189064

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Alefacept in the treatment of recalcitrant palmoplantar and erythrodermic psoriasis.
    Prossick TA, Belsito DV.
    Cutis; 2006 Sep; 78(3):178-80. PubMed ID: 17036660
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].
    Ortonne JP, Shear N, Shumack S, Henninger E, CLEAR Multinational Study Group.
    BMC Dermatol; 2005 Dec 16; 5():13. PubMed ID: 16359548
    [Abstract] [Full Text] [Related]

  • 8. Treatment of hand and foot psoriasis with emphasis on efalizumab.
    Kircik L.
    Skin Therapy Lett; 2007 Nov 16; 12(9):4-7. PubMed ID: 18087658
    [Abstract] [Full Text] [Related]

  • 9. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.
    Papp KA, Miller B, Gordon KB, Caro I, Kwon P, Compton PG, Leonardi CL, Efalizumab Study Group.
    J Am Acad Dermatol; 2006 Apr 16; 54(4 Suppl 1):S164-70. PubMed ID: 16488338
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice.
    Berends MA, Driessen RJ, Langewouters AM, Boezeman JB, Van De Kerkhof PC, De Jong EM.
    J Dermatolog Treat; 2007 Apr 16; 18(2):76-83. PubMed ID: 17520463
    [Abstract] [Full Text] [Related]

  • 12. New-onset, debilitating arthritis in psoriasis patients receiving efalizumab.
    Myers WA, Najarian D, Gottlieb AB.
    J Dermatolog Treat; 2006 Apr 16; 17(6):353-4. PubMed ID: 17853308
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis.
    Papp KA, Ho V, Langley R, Lynde C, Poulin Y, Shear N, Toole J, Zip C.
    J Cutan Med Surg; 2006 Apr 16; 9 Suppl 1():26-32. PubMed ID: 16633859
    [Abstract] [Full Text] [Related]

  • 15. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis.
    Leonardi C, Menter A, Hamilton T, Caro I, Xing B, Gottlieb AB.
    Br J Dermatol; 2008 May 16; 158(5):1107-16. PubMed ID: 18373710
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Severe psoriasis pustulosa palmaris et plantaris (Barber-Königsbeck) treated successfully with soluble tumour necrosis factor receptor fusion protein (etanercept).
    Kasche A, Pfab F, Hein R, Athanasiadis GI, Ollert M, Ring J, Eberlein-König B.
    J Eur Acad Dermatol Venereol; 2007 Feb 16; 21(2):255-7. PubMed ID: 17243968
    [No Abstract] [Full Text] [Related]

  • 19. Newer trends in the management of psoriasis at difficult to treat locations: scalp, palmoplantar disease and nails.
    Handa S.
    Indian J Dermatol Venereol Leprol; 2010 Feb 16; 76(6):634-44. PubMed ID: 21079306
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.